TY - JOUR T1 - Topiramate for pediatric migraine prevention JF - Canadian Family Physician JO - Can Fam Physician SP - 529 LP - 531 VL - 63 IS - 7 AU - Teeranai Sakulchit AU - Garth D. Meckler AU - Ran D. Goldman Y1 - 2017/07/01 UR - http://www.cfp.ca/content/63/7/529.abstract N2 - Question I have several teenagers in my clinic with migraine headache and some of them have frequent episodes that cause considerable interference with daily activity. I would like to offer them prophylactic therapy to reduce the frequency of their migraine episodes. Is topiramate an effective and safe option for adolescents?Answer Both Health Canada and the US Food and Drug Administration have approved the use of topiramate for migraine prevention in adults; however, only the US Food and Drug Administration has approved topiramate for migraine prophylaxis in adolescents 12 to 17 years of age. Although several studies support its effectiveness in preventing migraine, most of these studies are small; and a recent large multicentre, randomized placebo-controlled trial was stopped early when no benefit was shown over placebo. Adverse effects of topiramate are mild and typically resolve over time. The recommended dosage is 2 mg/kg per day, up to an adult dose of 100 mg/d. ER -